The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1491
ISSUE1491
March 28, 2016
Seebri Neohaler and Utibron Neohaler for COPD
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Seebri Neohaler and Utibron Neohaler for COPD
March 28, 2016 (Issue: 1491)
The FDA has approved two new inhalers for long-term
maintenance treatment of chronic obstructive
pulmonary disease (COPD). Seebri Neohaler
(Novartis) contains the long-acting anticholinergic
glycopyrrolate. Utibron Neohaler (Novartis)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.